YBGJ Company Profile and Key Details

Average 10-day trading volume of 111.82 thousand shares is significantly above the 3-month average of 27.26 thousand, indicating heightened recent market interest.

Valuation shows Yubo International Biotech Limited trading at a premium to the broader market with a P/E of -1.66.

Our AI price prediction model suggests that Yubo International Biotech Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

The stock is currently mid-range between its 52-week high and low $0.00 and $0.02. With a market capitalization of about $1.84 million, Yubo International Biotech Limited is classified as a micro-cap and shows lower-than-market volatility (beta ~0.71). Key stats such as the average daily volume over the past year has been around 5.40 thousand shares, trading with heavier-than-usual volume. Headquartered in Beijing, BE, Yubo International Biotech Limited operates in the Healthcare sector and the Medical - Instruments & Supplies industry. Led by CEO Yang Wang, the company employs approximately 14 people and listed since August 24, 2021. Yubo International Biotech Limited, operating through its various subsidiaries, primarily dedicates its efforts to the research, development, and practical application of endometrial stem cells.

Yubo International Biotech Limited trades at a P/E ratio of -1.66, slightly below the S&P 500 average, with a price-to-sales ratio of 13.7 and a price-to-book ratio of -0.7 indicating negative book value, which may reflect financial stress. The P/FCF stands at -4.97, also below market averages.

Yubo International Biotech Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.01. This means the shares are trading below this model’s fair value.